Global GLP-1 Agonist Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Agonist Market Research Report 2024
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
According to QYResearch’s new survey, global GLP-1 Agonist market is projected to reach US$ 44730 million in 2034, increasing from US$ 20600 million in 2022, with the CAGR of 16.6% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GLP-1 Agonist market research.
Key manufacturers engaged in the GLP-1 Agonist industry include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Agonist report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to QYResearch’s new survey, global GLP-1 Agonist market is projected to reach US$ 44730 million in 2034, increasing from US$ 20600 million in 2022, with the CAGR of 16.6% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GLP-1 Agonist market research.
Key manufacturers engaged in the GLP-1 Agonist industry include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Segment by Application
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Agonist report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices